Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A

Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A

Abstract Background Mutation analysis of circulating tumor DNA (ctDNA) is used for diagnosing lung cancer. This trial aimed to assess the efficacy of afatinib in treatment‐naïve patients with lung cancer harboring epidermal growth factor receptor mutations (EGFRm, exon 19 deletions or exon 21 point...

Full description

Bibliographic Details
Main Authors: Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Thoracic Cancer
Subjects:
Afatinib
circulating tumor DNA
EGFR mutation
non‐small cell lung carcinoma
Online Access:https://doi.org/10.1111/1759-7714.13763

Internet

https://doi.org/10.1111/1759-7714.13763

Similar Items